AGENUS INC Revenue Recognition, Milestone Method, Revenue Recognized
AGENUS INC (AGEN) reported Revenue Recognition, Milestone Method, Revenue Recognized of $25.00 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Notes
us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized · last filed 2018-05-10
- AGENUS INC revenue recognition, milestone method, revenue recognized for the quarter ending 2018-03-31 was $25.00M.
| Period end | Revenue Recognition, Milestone Method, Revenue Recognized 3 month |
|---|---|
| 2018-03-31 | $25.00M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |